Avibactam is a non-β-lactam β-lactamase inhibitor antibiotic, which is a new drug application for avibactam in combination with ceftazidime, and was approved by the FDA on February 25, 2015, for treating complicated urinary tract and complicated intra-abdominal Infections caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant gram-negative bacterial pathogens.
Avibactam - Synthetic Route 1
Synthetic Description
Reference: Liu, Chengxue; Tang, Feng; Zhang, Liming. Method for synthesizing β-lactamase inhibitor Avibactam. CN 106699756. (Assignee Zibo Xinquan Pharmaceutical Technology Service Co., Ltd., Peop. Rep. China)
Avibactam - Synthetic Route 2
Synthetic Description
Reference: Wang, Tao; Ying, Xiaoning; Du, Liangdong; Chen, Xinzhi; Wu, Guofeng. Synthesis method of avibactam sodium as β-lactamase inhibitor. CN 108239089. (Assignee Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory, Peop. Rep. China)
